Potential Impact of Revised NCI Eligibility Criteria Guidance: Prior Malignancy Exclusion in Breast Cancer Clinical Trials.

Autor:	Perez M; 1School of Medicine, UT Southwestern Medical Center, Dallas, Texas.; 2Now with Department of Radiology, University of Washington, Seattle, Washington., Murphy CC; 3School of Public Health, University of Texas Health Science Center at Houston, Dallas, Texas; and., Pruitt SL; 4Department of Population and Data Sciences.; 5Harold C. Simmons Comprehensive Cancer Center., Rashdan S; 5Harold C. Simmons Comprehensive Cancer Center.; 6Department of Internal Medicine, and., Rahimi A; 5Harold C. Simmons Comprehensive Cancer Center.; 7Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, Texas., Gerber DE; 4Department of Population and Data Sciences.; 5Harold C. Simmons Comprehensive Cancer Center.; 6Department of Internal Medicine, and.
Jazyk:	angličtina
Zdroj:	Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2022 Jul; Vol. 20 (7), pp. 792-799.e4.
DOI:	10.6004/jnccn.2022.7017
Abstrakt:	Background: Many individuals with cancer have survived a prior cancer and for this reason may have been excluded from clinical trials. Recent NCI guidance recommends including these individuals, especially when the risk of the prior malignancy interfering with either safety or efficacy endpoints is very low. Using breast cancer as an example, we determined the potential effect this policy change may have on clinical trial accrual. Patients and Methods: We reviewed protocols of NCI-sponsored breast cancer clinical trials activated in 1991 through 2016. We quantified prevalence of prior cancer-related exclusion criteria and assessed the association with trial characteristics using Fisher's exact tests. Using SEER data, we estimated the prevalence and timing of prior primary (nonbreast) cancer diagnoses among patients with breast cancer. Results: Among 87 clinical trials (total target enrollment, 137,253 patients), 77% excluded individuals with prior cancer, most commonly (79%) within the preceding 5 years. Among trials with radiographic response or toxicity endpoints, 69% excluded prior cancer. In SEER data, the prevalence of a prior (nonbreast) cancer diagnosis ranged from 5.7% to 7.7%, depending on breast cancer stage, of which 39% occurred within 5 years of the incident breast cancer. For trials excluding prior cancer, the estimated proportion of patients excluded for this reason ranged from 1.3% to 5.8%, with the estimated number of excluded patients ranging from 1 to 288. Conclusions: More than three-fourths of NCI-sponsored breast cancer clinical trials exclude patients with prior cancer, including almost 70% of trials with response or toxicity endpoints. Given that >5% of patients with breast cancer have a history of prior cancer, in large phase III trials this practice may exclude hundreds of patients. Following recent NCI eligibility guidance, the inclusion of patients with prior cancer on breast cancer trials may have a meaningful impact on accrual.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu